Meng, T.-G
The oral small-molecule inhibitor INCB001158 (CB-1158), targeting this axis, has entered first-inhuman phase I studies and has been explored in combination with PD-1 inhibitors, suggesting that relieving substrate depletion-driven immunosuppression is clinically feasible from a safety and pharmacodynamic perspective, although its therapeutic efficacy remains to be fully established (116)
Managing stress is not just good for your mind but also for your intestinal health
FDA-Approved Oral Semaglutide: The First GLP-1 Pill for Effective Weight Loss Oral semaglutide is the first FDA-approved GLP-1 pill for weight loss, offering a convenient and non-invasive alternative to injectable weight loss treatments
Prescriptions for GLP-1s have more than quadrupled since 2020, A 2024 KFF Health Poll survey found that as many as one in eight (12%) adults have taken a GLP-1 drug, with as many as 6% are currently using GLP-1 drugs
In addition, a variety of subgroup and sensitivity analyses confirmed the finding from the main analysis
